In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin

Ovarian cancer (OC) remains the deadliest gynecological malignancy, with alarming projections indicating a 42% increase in new cases and a 51% rise in mortality by 2040. This review explores the challenges in OC treatment, focusing on chemoresistance mechanisms and the potential of extracellular vesicles (EVs) as drug delivery agents. Despite advancements in treatment strategies, including cytoreductive surgery, platinum-based chemotherapy, and targeted therapies, the high recurrence rate underscores the need for innovative approaches. Key resistance mechanisms include drug efflux, apoptosis disruption, enhanced DNA repair, cancer stem cells, immune evasion, and the complex tumor microenvironment. Cancer-associated fibroblasts and extracellular vesicles play crucial roles in modulating the tumor microenvironment and facilitating chemoresistance. EVs, naturally occurring nanovesicles, emerge as promising drug carriers due to their low toxicity, high biocompatibility, and inherent targeting capabilities. They have shown potential in delivering chemotherapeutics like doxorubicin, cisplatin, and paclitaxel, as well as natural compounds such as curcumin and berry anthocyanidins, enhancing therapeutic efficacy while reducing systemic toxicity in OC models. However, challenges such as low production yields, heterogeneity, rapid clearance, and inefficient drug loading methods need to be addressed for clinical application. Ongoing research aims to optimize EV production, loading efficiency, and targeting, paving the way for novel and more effective therapeutic strategies in OC treatment. Overcoming these obstacles is crucial to unlocking the full potential of EV-based therapies and improving outcomes for OC patients.

show abstract

Tidal Triumphs

Parekh,

Gopal

2024

Advances in Medical Technologies and Clinical Practice

View full text Add to dashboard Cite

The book chapter explores the diverse array of metabolites found in marine life, from algae to sponges to corals, highlighting their unique chemical structures and biological activities. The book explores how these marine metabolites have promising anticancer effects, such as reduction of tumor growth, induction of apoptosis, and suppression of metastasis, through a thorough assessment of study data. The mechanisms of action that underlie these effects are also covered, providing insight into their potential as cutting-edge treatment medicines for a range of cancer types. “Marine Metabolites as Anticancer Agents” also addresses the difficulties and prospects of using these substances for drugs development, including problems with extraction, synthesis, and sustainability. Overall, it provides insightful information on the potential of chemicals produced from marine sources as a rich source of anticancer drugs, offering promise for the advancement of cancer treatment in the future.

show abstract

In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin

Cited by 4 publications

References 49 publications

CCR5 antagonist maraviroc alleviates doxorubicin-induced neuroinflammation and neurobehavioral deficiency by regulating NF-κB/NLRP3 signaling in a breast cancer mouse model

CCR5 antagonist maraviroc alleviates doxorubicin-induced neuroinflammation and neurobehavioral deficiency by regulating NF-κB/NLRP3 signaling in a breast cancer mouse model

Extracellular Vesicles in Ovarian Cancer: From Chemoresistance Mediators to Therapeutic Vectors

Tidal Triumphs

Contact Info

Product

Resources

About